Results 41 to 50 of about 1,398,102 (297)

MicroRNAs as therapeutic targets in cardiovascular disease

open access: yesThe Journal of Clinical Investigation, 2022
The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where ...
Bernhard Laggerbauer, Stefan Engelhardt
doaj   +1 more source

Breakthrough cancer pain - Still a challenge

open access: yes, 2012
Journal Article;Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%).
Escobar, Yolanda   +9 more
core   +1 more source

High content screening for drug discovery from traditional Chinese medicine

open access: yesChinese Medicine, 2019
Traditional Chinese medicine (TCM) represents the crystallization of Chinese wisdom and civilization. It has been valued as the renewable source for the discovery of novel drugs, owing to its long-term proved efficacy in human diseases and abundant ...
Jing Wang   +4 more
doaj   +1 more source

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben   +4 more
wiley   +1 more source

The Magic Eyes® of innovation: A metaphor for discovery [PDF]

open access: yes, 2012
The intersection of curiosity and connectivity: Magic Eyes® images can provide significant insight into how breakthrough innovators collect and connect dotsnot peer reviewedSubmitted by Bruce Vojak (bvojak@illinois.edu) on 2012-06-14T21:39:14Z No.
Vojak, Bruce A.
core  

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

Recent Progresses in Characterising Information Inequalities

open access: yesEntropy, 2011
In this paper, we present a revision on some of the recent progresses made in characterising and understanding information inequalities, which are the fundamental physical laws in communications and compression.
Terence Chan
doaj   +1 more source

Penicillium chrysogenum, a Vintage Model with a Cutting-Edge Profile in Biotechnology

open access: yesMicroorganisms, 2022
The discovery of penicillin entailed a decisive breakthrough in medicine. No other medical advance has ever had the same impact in the clinical practise. The fungus Penicillium chrysogenum (reclassified as P.
Francisco Fierro   +4 more
doaj   +1 more source

Breakthrough in Governance [PDF]

open access: yes, 2008
To describe and illustrate a breakthrough in the understanding of governance in schools arising from research in seven countries, and to provide guidelines to help every school to become as successful as the ...
Caldwell, Brian, Harris, Jessica
core  

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy